Fu et al. discovered that GAL could suppress pro-inflammatory signaling in synoviocytes through the inhibition of the NF-κB/NLRP3 pathway, making it a potential therapeutic agent for RA [192]. Here, NFKB1 is linked to rheumatoid arthritis.